AcquisitionsMay 8, 2026, 11:06 AM
Artivion to Acquire Endospan; Q1 Revenue +17.5% to $116.3M
AI Summary
Artivion, Inc. announced its decision to acquire Endospan for an upfront purchase price of $135.0 million, following the FDA approval of the NEXUS® Aortic Arch System in April 2026. This strategic move is supported by a $150.0 million borrowing from a new delayed draw term loan facility. Concurrently, the company reported strong first-quarter 2026 financial results, with revenues increasing by 17.5% to $116.3 million and a return to net income of $1.4 million, compared to a net loss in the prior year.
Key Highlights
- Artivion elected to acquire Endospan for an upfront purchase price of $135.0 million following FDA approval of NEXUS® Aortic Arch System in April 2026.
- Total revenues increased 17.5% to $116.3 million for Q1 2026, up from $99.0 million in Q1 2025.
- Net income was $1.4 million ($0.03 EPS) for Q1 2026, a swing from a net loss of $(0.5) million ($(0.01) EPS) in Q1 2025.
- Operating income surged 169.8% to $5.8 million in Q1 2026, compared to $2.1 million in Q1 2025.
- Gross margin improved to $75.4 million in Q1 2026, up from $63.6 million in Q1 2025.
- Net cash flows from operating activities turned positive at $1.2 million in Q1 2026, compared to $(17.0) million used in Q1 2025.
- Artivion borrowed $150.0 million under the New Delayed Draw Term Loan Facility to fund the Endospan acquisition.
- Maturity date of existing term loans and revolving credit facility extended by one year to January 18, 2031.
Price Impact
More from AORT